Flavor is earthy
Eli Lilly has historically prioritized R&D, but shows signs of shifting toward greater shareholder enrichment: With a ratio of 0.61, Eli Lilly spent more on R&D than on shareholder returns from 2020 to 2024
[PMID: 30907424] doi: 10.1093/ije/dyz038 Simon GE , Shortreed SM , Boggs JM , et al
Understanding your genetic predispositions and current metabolic biomarkers can support a more informed conversation with your provider about which compounded GLP-1 formulation, dosing approach, and monitoring strategy align best with your individual health goals
Each pathway contributes differently to weight loss, metabolic improvement, and the side effects you experience
Individuals with a history of thyroid cancer should discuss this with their provider before starting treatment